Medical Weight Loss in Patong, Phuket: Ozempic, Wegovy, Mounjaro and Evidence-Based Care
Clinically reviewed by the Doctor Patong Takecare Clinic medical team.
Medical weight loss in Patong is a doctor-led programme combining lifestyle change with prescription medication when clinically appropriate. We offer baseline assessment, blood work, GLP-1 therapy (Ozempic, Wegovy, Mounjaro) where indicated, and structured monthly review. Eligibility is BMI 30 or above, or BMI 27 with a weight-related condition such as type 2 diabetes, hypertension, or sleep apnoea. A 5 to 10 percent weight reduction delivers meaningful health gains.
WhatsApp +66 95 073 5550 | Call +66 81 718 9080 | Find us on Maps
Our medical team sees a steady flow of patients in Patong asking about Ozempic, Wegovy, and Mounjaro after reading about them online or hearing about them from friends. We treat weight as a medical condition with measurable risks, not as a cosmetic concern. Our role is to assess whether pharmacotherapy is appropriate, set realistic targets, and monitor safety month by month. We will be honest if medication is not the right step for you.
Who benefits from medical weight loss
Medical weight loss is indicated for adults with a body mass index of 30 or above, which is classified as obesity. It is also indicated at a BMI of 27 or above when at least one weight-related condition is present, including type 2 diabetes, pre-diabetes, high blood pressure, abnormal cholesterol (dyslipidaemia), obstructive sleep apnoea, fatty liver (non-alcoholic fatty liver disease or NAFLD), or polycystic ovary syndrome (PCOS). We typically expect a trial of structured lifestyle change for three to six months before adding medication, though we shorten that window if a comorbidity is already causing harm. Below BMI 27 with no comorbidity, there is no medical indication and we will decline to prescribe.
The lifestyle foundation that medication does not replace
Every plan we build starts with a daily calorie deficit of roughly 500 to 750 kcal below maintenance, anchored to a Mediterranean or DASH eating pattern because these have the strongest evidence base for both weight and cardiometabolic outcomes. Protein intake of 1.2 to 1.6 grams per kilogram of body weight protects lean muscle mass, which matters more on GLP-1 therapy than on diet alone. We ask for 150 to 300 minutes of moderate aerobic activity per week plus resistance training on at least two days, because resistance work is the single best defence against muscle loss during rapid weight reduction. Sleep of seven hours or more matters: short sleep raises the hunger hormone ghrelin and lowers the satiety hormone leptin, which makes any deficit harder to hold. Stress and cortisol management, although harder to quantify, change appetite and central fat storage. A sustained 5 to 10 percent weight loss produces measurable improvement in HbA1c, blood pressure, and lipid profile, and that is the first target we set.
Pharmacotherapy: medication options
When lifestyle measures alone are not enough and eligibility is met, we discuss the following options. GLP-1 receptor agonists are the most effective class currently available. Costs in the table are indicative monthly retail ranges in Phuket, dependent on dose and pharmacy supply.
| Medication | Route | Average weight loss | Monthly cost (indicative) | Key side effects |
|---|---|---|---|---|
| Semaglutide (Ozempic, Wegovy, Rybelsus) | Weekly injection (Ozempic, Wegovy); daily tablet (Rybelsus) | About 15 percent over 68 weeks at full dose (STEP trials) | THB 12,000 to 18,000 | Nausea, vomiting, constipation, rare pancreatitis |
| Tirzepatide (Mounjaro, Zepbound) | Weekly injection | 20 to 22 percent over 72 weeks at 15 mg (SURMOUNT trials) | THB 18,000 to 28,000 | Nausea, diarrhoea, reduced appetite, rare gallstones |
| Liraglutide (Saxenda) | Daily injection | 5 to 8 percent | THB 10,000 to 14,000 | Similar GI effects; weaker, daily dosing |
| Phentermine with topiramate (Qsymia) | Daily oral | 8 to 10 percent, short term | THB 3,000 to 6,000 | Insomnia, raised heart rate, cardiovascular caution |
| Naltrexone with bupropion (Contrave) | Daily oral | 5 percent | THB 4,000 to 7,000 | Nausea, insomnia, mood change, seizure risk in some |
| Orlistat (Xenical) 120 mg three times daily | Oral with meals | 3 to 5 percent | THB 2,500 to 4,500 | Oily stools, urgency, fat-soluble vitamin loss |
Most GLP-1 side effects (nausea, vomiting, constipation, diarrhoea) appear during dose titration and settle with slow up-titration and antiemetics where needed. Rare adverse events include pancreatitis, gallstones with rapid weight loss, and delayed gastric emptying. GLP-1 agents are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). Lean mass loss accompanies rapid weight reduction, which is why we insist on adequate protein and resistance training throughout treatment.
Monitoring on treatment
We review weight and waist circumference every four weeks during titration, then every three months. Blood pressure is checked at every visit. HbA1c is repeated every three to six months for patients with diabetes or pre-diabetes. Lipids and liver function are repeated every six to twelve months. We screen mood, since bupropion-containing regimens and rapid lifestyle change can shift mental health. If a patient has lost less than 5 percent of starting weight after twelve weeks at the maximum tolerated dose, current guidance is to discontinue rather than continue indefinitely.
Surgical referral
For BMI 40 or above, or BMI 35 or above with a serious comorbidity, bariatric surgery is the most durable intervention. We refer to Bangkok Hospital Phuket or an equivalent tertiary centre for assessment. Options include Roux-en-Y gastric bypass, sleeve gastrectomy, and less invasive intragastric balloon devices that sit in the stomach for around six months. Lipotropic, B12, and MIC injections are popular locally, but the evidence base is thin and we will say so plainly: they are not a substitute for diet, medication, or exercise.
BMI under 27 with no comorbidity (no medical indication). Active eating disorder including anorexia nervosa, bulimia, or binge eating disorder that needs specialist support first. Pregnancy or planning pregnancy within two months (GLP-1 must be stopped at least two months before conception). Personal or family history of medullary thyroid cancer or MEN2 syndrome. Type 1 diabetes (different treatment framework). Severe gastroparesis or symptomatic gallstone disease.
Your BMI is 30 or above; your BMI is 27 or above and you have diabetes, pre-diabetes, high blood pressure, sleep apnoea, fatty liver, or PCOS; you have lost less than 5 percent of body weight after six months of genuine lifestyle effort; unexplained weight gain has appeared with fatigue, cold intolerance, or new mood symptoms; or you are already self-sourcing GLP-1 medication without medical supervision.
GLP-1 medication is effective, not magical. The STEP-4 trial showed that patients who stopped semaglutide regained roughly two-thirds of lost weight within a year, so we plan continuation strategy from day one. Compounded or grey-market semaglutide sold through some clinics and online sources carries real safety risks (dosing errors, contamination, unverified active ingredient), so we prescribe only pharmaceutical-grade Ozempic, Wegovy, or Mounjaro from licensed pharmacies. Body composition matters more than the scale: protect lean mass with protein intake and resistance training, otherwise rapid loss leaves you lighter but metabolically weaker.
Sustained weight maintenance depends on resistance training at least twice weekly, protein intake of 1.2 to 1.6 g/kg, seven or more hours of sleep, and a dietary pattern you can hold for years (Mediterranean and DASH are the most studied). For patients who respond well to GLP-1 therapy, the current evidence supports continuation at a maintenance dose rather than abrupt discontinuation. We review the plan annually and adjust dose downward if weight is stable.
What we do at the clinic
Your first visit covers a clinical history, examination, BMI and waist measurement, and baseline blood work covering HbA1c, fasting lipids, liver and kidney function, thyroid function (TSH), and full blood count. We rule out secondary causes of weight gain (hypothyroidism, Cushing’s syndrome, fluid retention from cardiac, renal, or hepatic disease, and medication side effects from antipsychotics, antidepressants, or steroids). We then build a treatment plan with realistic targets, prescribe pharmacotherapy if appropriate, and review monthly during titration. Nutritionist referral is available where useful.
Summary
Medical weight loss is a serious treatment, not a beauty service. The evidence base for GLP-1 therapy is strong when prescribed correctly, monitored, and combined with lifestyle change. Five to ten percent weight loss is a meaningful clinical target that improves diabetes, blood pressure, and lipids. Doctor Patong Takecare Clinic offers eligibility assessment, baseline blood work, pharmaceutical-grade prescription, and structured monthly review.
“We prescribe weight-loss medication only where it is medically indicated, only as pharmaceutical-grade product, and always alongside the lifestyle work that decides whether the loss lasts.” Doctor Patong Takecare Clinic medical team.
Frequently asked questions
Do I qualify for Ozempic or Mounjaro at your clinic?
You qualify if your BMI is 30 or above, or 27 or above with a weight-related condition such as type 2 diabetes, pre-diabetes, hypertension, sleep apnoea, fatty liver, or PCOS. Below BMI 27 with no comorbidity, we will not prescribe. We confirm eligibility at the first visit with examination, BMI, and blood work.
What side effects should I expect on a GLP-1 medication?
Nausea, mild vomiting, constipation, or diarrhoea during the first weeks of each dose increase. These usually settle with slow titration and short-term antiemetic support. Rare risks include pancreatitis and gallstone formation with rapid weight loss. We screen for contraindications including medullary thyroid cancer history and pregnancy plans before starting.
What is the monthly cost in Phuket?
Indicative monthly costs in Patong are roughly THB 12,000 to 18,000 for semaglutide (Ozempic or Wegovy) and THB 18,000 to 28,000 for tirzepatide (Mounjaro), depending on dose. Oral options such as orlistat or Contrave run lower. We confirm pricing at consultation since pharmacy supply and dose change the figure.
How long do I take the medication?
Current evidence supports continued treatment at a maintenance dose for as long as the medication is tolerated, since stopping reliably leads to weight regain in most patients. We review yearly and adjust the dose downward when weight is stable. If response is poor at twelve weeks on the maximum tolerated dose, we discontinue rather than persist.
Will I regain weight if I stop?
Yes, in most cases. The STEP-4 study showed roughly two-thirds of lost weight returned within a year of stopping semaglutide. This is why we plan continuation and maintenance from the first visit, and why we emphasise the lifestyle, protein, and resistance training elements that hold weight even if medication ends.
Can I lose weight with lifestyle change alone instead of medication?
Yes, many patients can. We always trial structured lifestyle change first for three to six months, unless a comorbidity is already causing harm. Medication adds on top when lifestyle alone has not delivered 5 percent weight loss. Lifestyle is never optional; medication never replaces it.
Sources
NICE NG246: Overweight and obesity management. WHO: Obesity and overweight. ADA / EASD consensus on obesity in type 2 diabetes.
WhatsApp +66 95 073 5550 | Call +66 81 718 9080 | Find us on Maps
Obesity, BMI, body composition, type 2 diabetes, pre-diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, NAFLD, PCOS, semaglutide, Ozempic, Wegovy, Rybelsus, tirzepatide, Mounjaro, Zepbound, liraglutide, Saxenda, phentermine, topiramate, naltrexone, bupropion, orlistat, Xenical, GLP-1 receptor agonist, GIP, bariatric surgery, sleeve gastrectomy, Roux-en-Y gastric bypass, intragastric balloon, Mediterranean diet, DASH diet, resistance training, STEP trial, SURMOUNT trial, MEN2, medullary thyroid carcinoma.